LOLA (l-ornithine-l-aspartate) is not frequently used as there are still some reservations about its benefits. This study assesses the effectiveness and safety of LOLA in the management of hepatic ...

Ornithine transcarbamylase (OTC) deficiency is a urea cycle disorder caused by a genetic mutation in the OTC gene resulting in excess levels of ammonia in the blood. This accumulation can lead to ...

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting. March 12, 2025 08:00 AM Eastern Daylight Time.